More schools stock overdose reversal meds, but others worry about stigma

The investment is set to propel the development of the company’s lead candidates, MZE829 and MZE782. Credit: Mongkolchon Akesin/Shutterstock. Maze Therapeutics has completed a Series

An acute com­pe­ti­tion is emerg­ing among drug de­vel­op­ers look­ing at a rare neu­ro­log­i­cal dis­or­der known as chron­ic in­flam­ma­to­ry de­myeli­nat­ing polyneu­ropa­thy, or CIDP, and Wall Street